ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[Erianin inhibits proliferation and migration of breast cancer cells
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the effect of erianin on proliferation, migration, invasion, and apoptosis of breast cancer cells and the underlying mechanisms.
methodsBreast cancer cell lines T-47D and MCF-7 treated with 0, 12.5, 25, 50, and 100 nmol/L erianin for 12, 24, 36, 48, and 72 h were examined for cell viability using CCK-8 assay. The effects of erianin on cell proliferation, migration, invasion, senescence and apoptosis were evaluated using clone formation, wound healing, Transwell invasion, and senescence assays and flow cytometry. mRNA microarray analysis and the Enrichr database were used to explore the biological functions of erianin. Western blotting was used to detect the changes in protein expressions related to apoptosis, epithelial-mesenchymal transition (EMT), and the Wnt/β-catenin pathway.
resultsErianin concentration-dependently inhibited cell viability, proliferation, migration, and invasion, and promoted senescence in T-47D and MCF-7 cells. Microarray analysis identified 1064 differentially expressed genes (DEGs), including 948 upregulated and 116 downregulated genes, which were involved primarily in EMT regulation, collagen-containing extracellular matrix, calcium ion binding, the PI3K-Akt signaling pathway, the Wnt/β-catenin signaling pathway, and apoptosis. Flow cytometry confirmed that erianin concentration-dependently induced apoptosis in the breast cancer cells, upregulated the expressions of Bax and caspase-3, decreased Bcl-2 expression, and lowered the expressions of EMT-related proteins (Snail, N-cadherin, and β‑catenin) and Wnt/β‑catenin signaling proteins (TCF4, Cyclin D1, and c-Myc). In the breast cancer cells treated with 100 nmol/L erianin, the application of a Wnt/β‑catenin agonist significantly increased the proteins expressions of TCF4, Cyclin D1, and c-Myc.
conclusionsErianin inhibits proliferation, migration, and invasion and induces senescence and apoptosis in breast cancer cells possibly by suppressing the Wnt/β-catenin signaling pathway to induce cell apoptosis and reverse EMT of the cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.